Gamma Secretase Pipeline Review, H2 2020 - ResearchAndMarkets.com
The "Gamma Secretase - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Gamma Secretase - Pipeline Review, H2 2020' outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
'Gamma Secretase - Pipeline Review, H2 2020'; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.
Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain.
The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.
Scope
The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)
The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects
The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics
Key Topics Covered:
Introduction
Report Coverage
Overview
Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Companies Involved in Therapeutics Development
Adipo Therapeutics LLC
AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
F. Hoffmann-La Roche Ltd
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc
Drug Profiles
ACD-679
ACD-680
AL-101
AL-102
crenigacestat
dibenzazepine
EF-005
Gene Therapy to Activate PSEN1 for Heart Failure
GSI-34
LP-226A1
LY-3056480
NGP-555
nirogacestat hydrobromide
Peptides to Inhibit PSEN1 for Alzheimer's Disease
PIPE-505
RO-7185876
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease
Small Molecules to Inhibit Gamma Secretase for Hearing Loss
Small Molecules to Inhibit PSEN1 for Alzheimer's Disease
Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease
Dormant Products
Discontinued Products
Product Development Milestones
Featured News & Press Releases
Sep 18, 2020: Ayala Pharmaceuticals presents positive interim data from phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma with notch activating mutations at ESMO 2020
Sep 16, 2020: SpringWorks Therapeutics announces collaboration with Children's Oncology Group to conduct a phase 2 clinical trial of nirogacestat in pediatric patients with desmoid tumors and reports publication of nirogacestat case series in pediatric/young adult desmoid tumor patients
Sep 14, 2020: Ayala Pharmaceuticals to host virtual KOL event reviewing interim data presented at ESMO 2020 from ongoing phase 2 accuracy trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma
Jul 27, 2020: Ayala Pharmaceuticals to present updated data from ongoing phase 2 ACCURACY trial of AL101 for the treatment of R/M adenoid cystic carcinoma at the European Society for Medical Oncology (ESMO) virtual congress 2020
Jul 23, 2020: Pipeline Therapeutics initiates Phase 1/2a clinical trial of PIPE-505 in sensorineural hearing loss
Jul 22, 2020: SpringWorks Therapeutics announces full enrollment of phase 3 DeFi trial evaluating nirogacestat in adult patients with desmoid tumors
Jun 22, 2020: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating Nirogacestat and GlaxoSmithKline's Belantamab Mafodotin for the treatment of Relapsed or Refractory Multiple Myeloma
Mar 18, 2020: SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039
Mar 03, 2020: Ayala Pharmaceuticals granted U.S. FDA Fast Track Designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma
Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline's BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting
Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO
Sep 26, 2019: SpringWorks receives orphan status for nirogacestat in Europe
Sep 19, 2019: Ayala Pharmaceuticals announces presentation at the European Society for Medical Oncology (ESMO)
Aug 30, 2019: SpringWorks receives breakthrough status for desmoid tumour drug
May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mx7f1s.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005718/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900